Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.

Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, Delgado B, Bayme M, Koretz M.

Ann Oncol. 2011 Nov;22(11):2381-6. doi: 10.1093/annonc/mdq769. Epub 2011 Mar 1.

2.
3.

The influence of a gene expression profile on breast cancer decisions.

Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW.

J Surg Oncol. 2009 May 1;99(6):319-23. doi: 10.1002/jso.21244.

PMID:
19204954
4.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

Ann Oncol. 2012 Mar;23(3):625-31. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6.

5.

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G.

Oncologist. 2011;16(11):1520-6. doi: 10.1634/theoncologist.2011-0045. Epub 2011 Oct 20.

6.

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

Eiermann W, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, Witzel I, Eidtmann H, Bachinger A, Hell S, Blohmer J.

Ann Oncol. 2013 Mar;24(3):618-24. doi: 10.1093/annonc/mds512. Epub 2012 Nov 7.

7.

Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.

Markopoulos C, Xepapadakis G, Venizelos V, Tsiftsoglou A, Misitzis J, Panoussis D, Antonopoulou Z, Stathoulopoulou M, Zobolas V, Gogas H.

Eur J Surg Oncol. 2012 May;38(5):413-9. doi: 10.1016/j.ejso.2012.02.183. Epub 2012 Mar 17.

PMID:
22425282
8.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N.

J Clin Oncol. 2006 Aug 10;24(23):3726-34. Epub 2006 May 23.

10.

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI.

J Clin Oncol. 2016 Apr 1;34(10):1065-71. doi: 10.1200/JCO.2015.62.8503. Epub 2015 Nov 23.

PMID:
26598746
11.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
13.

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.

Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B.

Cancer. 2008 Feb 15;112(4):731-6.

14.

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, Nakano S, Fukutomi T, Hara K, Ichihara S, Lin Y, Kikuchi S.

J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.

PMID:
19946706
15.

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA.

J Oncol Pract. 2013 Jul;9(4):182-7. doi: 10.1200/JOP.2012.000638. Epub 2013 Feb 12.

17.

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.

Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.

PMID:
18809056
18.

Gene expression profiling for breast cancer prognosis in Chinese populations.

Sun B, Zhang F, Wu SK, Guo X, Zhang LL, Jiang ZF, Wang DM, Song ST.

Breast J. 2011 Mar-Apr;17(2):172-9. doi: 10.1111/j.1524-4741.2010.01049.x.

PMID:
21410584
19.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
20.

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Hornberger J, Cosler LE, Lyman GH.

Am J Manag Care. 2005 May;11(5):313-24. Erratum in: Am J Manag Care. 2005 Aug;11(8):476.

Items per page

Supplemental Content

Write to the Help Desk